menu
Conference

Next-Gen Immuno-Oncology Congress

Meet with Q2 Solutions virtually and learn how we can help with your immuno-oncology needs

Virtual Event | June 25, 2020 - June 26, 2020 | 09:00 - 18:00 Add to Calendar
Schedule a Virtual Meeting

About This Event

Join us for the 3rd Annual Markets and Markets Next-Gen Immuno-Oncology Congress. This year's event is fully virtual.

Don't miss Patrick Hurban's presentation on Day 1

Title : Perspective on using Tumor Microenvironment Gene Signature to provide Insight on Prognostic and Drug Response Predictive Immune Markers

Date: Thursday June 25, 2020

Time: 1:50PM ET

Summary:

  • A background on Tumor-Immune activity and the Tumor Microenvironment (TME)
  • The development of Immune Landscape Signatures
  • How to apply Immune Landscape Signatures
    • The association with key endpoints, response-to-therapy
    • The relationship between Immune Landscape Signatures and Tumor Mutational Burden (TMB)

We look forward to meeting you virtually.

Register for Event

Speakers

Patrick Hurban, Ph.D.
Genomics

Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes. 

Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology. 

Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.